Business Context and Reporting Period
Company: Matinas Biopharma Holdings, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: June 3, 2017
Reporting Period: Event-based disclosure regarding interim clinical study results.
The Company is an emerging growth company focused on the development of MAT2203, an orally-administered therapeutic. This filing discloses interim results from a Phase 2a Clinical Study conducted by the National Institutes of Health (NIH) for the treatment of Chronic Refractory Mucocutaneous Candidiasis.
Key Financial Metrics
This Form 8-K is a disclosure of a material event (clinical trial results) and does not contain financial statements. Consequently, the filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes
The primary material change reported is the release of interim data from the Phase 2a Clinical Study of MAT2203. The Company announced these results via a press release (Exhibit 99.1) and scheduled an investor conference call for June 5, 2017, utilizing a presentation (Exhibit 99.2).
Guidance, Outlook, and Risks
Management Commentary: The Company intends to discuss the interim results during its investor conference call on June 5, 2017.
Regulatory Status: The information contained in this Item 7.01, including the attached press release and presentation, is not deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 and is not incorporated by reference into other filings unless expressly stated.
Investor Verification Checklist
- Review the attached Press Release (Exhibit 99.1) for specific interim data points from the Phase 2a study.
- Examine the Investor Presentation (Exhibit 99.2) for detailed analysis of the clinical results.
- Verify the outcome of the investor conference call held on June 5, 2017, for management's interpretation of the data.
- Monitor future filings for any updates on the study's final results or regulatory implications.